Navigation Links
DSMB Supports Continuation of Phase 3 AGENDA Trial of Genasense(R) in Advanced Melanoma
Date:3/31/2008

g

to maintain the Company's planned operations;

-- the adequacy of the Company's patents and proprietary rights;

-- the impact of litigation that has been brought against the Company

and its officers and directors and any proposed settlement of such

litigation;

-- the Company's ability to retain compliance with the NASDAQ's listing

qualifications; and

-- the other risks described under Certain Risks and Uncertainties

Related to the Company's Business, as contained in the Company's

Annual Report on Form 10-K and Quarterly Report on Form 10-Q.

The Company does not undertake to update any forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2007 and its most recent quarterly report on Form 10-Q.

CONTACT:

Nichol Harber

Genta Investor Relations

908-286-3980

info@genta.com


'/>"/>
SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. DSMB Again Supports Continuation of the Phase III Clinical Trial of Medidur(TM) FA for the Treatment of DME
2. Evanston Northwestern Healthcare Researchers Explain Effects of Large-Scale, Universal MRSA Surveillance Program That Supports Expanded Intervention
3. ACR Supports American Cancer Society Inclusion of CT Colonography (Virtual Colonoscopy) as Recommended Screening Tool for Colorectal Cancer in New Screening Guidelines
4. New Clinical Data Further Supports Chromium Picolinates Role in Enhancing Brain Activity in Older Adults
5. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
6. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
7. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
8. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
9. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
10. New Data from the Framingham Heart Study Supports PAT Technology to Diagnose Early Cardiovascular Disease
11. Cost-Effectiveness Study Supports Use of EUFLEXXA(TM) by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... NEW YORK , July 25, 2014  Smile ... selected to showcase their Virtual Surgery Simulator among ... 2014, which will take place in Washington, ... for the Performing Arts. "Smile Train ... BioDigital alongside the talented community of innovators in health ...
(Date:7/25/2014)... Kan. , July 25, 2014 /PRNewswire-iReach/ -- ... and TCGRx, of Powers Lake, Wisconsin ... partners in a distribution and co-marketing agreement allowing ... retail pharmacies throughout the United States ... robotics-based pharmacy management and workflow systems to retail ...
(Date:7/25/2014)... July 25, 2014 /PRNewswire-iReach/ -- Full Service CRO ... the new Vice President of Business Development. Peter has ... in a number of different business development positions with ... positions were primarily related to business development/sales management and ... 30 years makes him a key and strategic asset ...
Breaking Medicine Technology:Smile Train and BioDigital Selected to Showcase Virtual Surgery Simulator in The Hive at TEDMED 2014 2Smile Train and BioDigital Selected to Showcase Virtual Surgery Simulator in The Hive at TEDMED 2014 3ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 2ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 3Contract Research Organization WCCT Global Welcomes Peter Nieto as Vice President of Business Development 2
... ANTONIO, Feb. 28, 2011 Advanced Cell Diagnostics, ... clinical study utilizing RNAscope™ technology to detect human ... of head and neck cancer. HPV status determined ... of patient outcome and highly concordant with that ...
... 2011 PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) ... dividend policy for 2011 and beyond and declared that the four ... be $0.15 per share of common stock.  The $0.15 dividends will ... 15 to all stockholders who own shares of PDL on March ...
Cached Medicine Technology:ACD Announces Clinical Study Results Using its RNAscope™ Technology 2ACD Announces Clinical Study Results Using its RNAscope™ Technology 3PDL BioPharma Announces Regular Quarterly Dividend Policy 2
(Date:7/25/2014)... (PRWEB) July 25, 2014 Parkulture ... co-founders, professional stuntman and parkour instructor, Jared “JJ” Woods, ... sports competition show, American Ninja Warrior. The show will ... at 9PM and will rerun on the new Esquire ... a long-time Miami resident, has been balancing careers as ...
(Date:7/25/2014)... 2014 The new report “Carbohydrase ... Pharmaceuticals and Others), by Type (Amylases, Cellulases, and ... - Global Trends & Forecasts to 2019", by ... the global Carbohydrase market with analysis of trends, ... segmented and values are forecasted on the basis ...
(Date:7/25/2014)... NJ (PRWEB) July 25, 2014 CarePoint ... Dr. Edward Boylan, has joined our network, CarePoint ... the community. Hundreds of highly skilled and experienced physicians ... top doctors and practices in Hudson County, representing a ... Health’s commitment to provide the highest quality care to ...
(Date:7/25/2014)... In today’s technological era, every organization ... devices. This benefits the organization in various ways. But ... which can destroy the confidential information and processes of ... Compliance (EGRC) manage and protect the enterprise from various ... loss in dollars to the comp may. The equipment's ...
(Date:7/25/2014)... Eye & Vision has announced the celebration ... by expanding a new specialized ocular and vision service ... clinic. , By acquiring specialized Visual Evoked Potential (VEP) ... problems, patients with vision loss in need of visual ... implementation of this specialized vision testing clinic. The new ...
Breaking Medicine News(10 mins):Health News:Jared “JJ” Woods Prepares for American Ninja Warrior City Finals 2Health News:Jared “JJ” Woods Prepares for American Ninja Warrior City Finals 3Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 2Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 3Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 4Health News:Dr. Boylan Joins CarePoint Health Medical Group 2Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 5Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 6Health News:Eye & Vision, a Leading Eye Doctor Group in Richardson, Celebrate Milestone and Expand Scope of Specialized Eye Care 2Health News:Eye & Vision, a Leading Eye Doctor Group in Richardson, Celebrate Milestone and Expand Scope of Specialized Eye Care 3
... The official journal of the American Neurological Association, examined ... were devastated in FTD//. ,Von Economo neurons ... have evolved in a select group of socially complex ... whales. Across species, VENs are localized to frontal brain ...
... service use among a group of newly homeless adolescents ... if differences existed// among those who had returned home ... that period, 63 percent had returned home, with the ... most youths in the study sought out health care ...
... that 95 percent of Americans have pre marital sex-sex before ... men //and women as far back as the 1940 were ... hundreds of millions of dollars advising young adults to wait ... official disagreed and opined that even if the programs don't ...
... predictions of influenza activity 2-4 weeks in advance in the ... there are outbreaks of influenza any time of the year, ... as a caution to people to opt for preventive measures ... about a future event buy and sell shares based on ...
... and Eugenics were developed by scientists with a vision to ... genes from the gene pool. // ,But now it ... Though it sounds absurd, ‘why should anyone order for a ... dwarfism, it only means making babies like them. ...
... blood to the part of the brain affected is interrupted, ... or die, impairing local brain function. // ... stroke, new blood vessels begin to form, and, like marching ... area to aid the regeneration process. What’s not known is ...
Cached Medicine News:Health News:A Study Finds VENs Devastated in FTD 2Health News:The Outbreak of Influenza is Now Predicted 2Health News:Can Defective Babies Be Made To Order? 2Health News:Cellular Cues Identified for Stroke Recovery 2
... adjusted for perfect focus where it's needed ... This, along with Keeler's wide angle light ... the patient's pupil size, you will see ... Lithium-ion technology provides a longer life battery ...
... adjusted for perfect focus where it's needed ... This, along with Keeler's wide angle light ... the patient's pupil size, you will see ... Lithium-ion technology provides a longer life battery ...
... Keeler ophthalmoscopes are individually adjusted for ... the eye, not on paper. This, along ... infinity focus, ensures that whatever the patient's ... and largest field of view. Lithium-ion technology ...
The Beta 200S combines Heine's patented aspherical optics (U.S. Pat. 4.963.014) and a single-step Rekoss disk with a range of 36 to +38 dpt. to provide perfectly-focused images even in cases of high ...
Medicine Products: